Receptor-mediated cascade targeting strategies for the application to medical diagnoses and therapeutics of glioma
Source abstract
Abstract
Glioma is the most frequent tumor of the central nervous system with high morbidity and mortality. Despite the great progress to exploit diagnostic and therapeutic tools, the treatment of glioma remains a huge challenge. The special anatomical structure of the brain, in particular, the blood–brain barrier (BBB) and the blood–brain tumor barrier (BBTB), limits the drug delivery efficacy and causes the diagnosis and treatment failure of various drugs. This encourages researchers to develop some novel therapeutic strategies to address these problems. Currently, receptor-mediated cascade targeting (RMCT) strategies, with targeting ligands targeting BBB and BBTB simultaneously, have been developed to overcome the barriers and are expected to accurately deliver drugs to glioma for diagnosis and therapy. In this review, we summarize the receptors and targeting ligands used in glioma, the categories of RMCT strategies, and the nanoplatforms used in RMCT strategies. We believe that the RMCT strategies will provide a reference for glioma treatment in the clinic and improve the life quality of patients with glioma.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Drug Transport and Resistance Mechanisms · Glioma Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Ali ES, Sharker SM, Islam MT, Khan IN, Shaw S, Rahman MA et al (2021) Targeting cancer cells with nanotherapeutics and nanodiagnostics: current status and future perspectives. Semin Cancer Biol 69:52–68. https://doi.org/10.1016/j.semcancer.2020.01.01110.1016/j.semcancer.2020.01.011 ↗
2. Altshuler DB, Kadiyala P, Nunez FJ, Nunez FM, Carney S, Alghamri MS et al (2020) Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opin Biol Ther 20:305–317. https://doi.org/10.1080/14712598.2020.171308510.1080/14712598.2020.1713085 ↗
3. Banerjee K, Nunez FJ, Haase S, McClellan BL, Faisal SM, Carney SV et al (2021) Current approaches for glioma gene therapy and virotherapy. Front Mol Neurosci 14:621831. https://doi.org/10.3389/fnmol.2021.62183110.3389/fnmol.2021.621831 ↗
4. Bi YK, Liu LS, Lu YF, Sun T, Shen C, Chen XL et al (2016) T7 peptide-functionalized PEG-PLGA micelles loaded with carmustine for targeting therapy of glioma. Acs Appl Mater Inter 8:27465–27473. https://doi.org/10.1021/acsami.6b0557210.1021/acsami.6b05572 ↗
5. Bi JF, Chowdhry S, Wu SH, Zhang WJ, Masui K, Mischel PS (2020) Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer 20:57–70. https://doi.org/10.1038/s41568-019-0226-510.1038/s41568-019-0226-5 ↗
6. Bonnin DAA, Ran C, Havrda MC, Liu H, Hitoshi Y, Zhang ZH et al (2017) Insulin-mediated signaling facilitates resistance to PDGFR inhibition in proneural hPDGFB-driven gliomas. Mol Cancer Ther 16:705–716. https://doi.org/10.1158/1535-7163.MCT-16-061610.1158/1535-7163.MCT-16-0616 ↗
7. Byeon HJ, le Thao Q, Lee S, Min SY, Lee ES, Shin BS et al (2016) Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. Journal of Controlled Release : Official Journal of the Controlled Release Society 225:301–313. https://doi.org/10.1016/j.jconrel.2016.01.04610.1016/j.jconrel.2016.01.046 ↗
8. Carpenter AB, Carpenter AM, Aiken R, Hanft S (2021) Oncolytic virus in gliomas: a review of human clinical investigations. Ann Oncol 32:968–982. https://doi.org/10.1016/j.annonc.2021.03.19710.1016/j.annonc.2021.03.197 ↗
9. Chai ZL, Hu XF, Wei XL, Zhan CY, Lu LW, Jiang K et al (2017) A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Control Release 264:102–111. https://doi.org/10.1016/j.jconrel.2017.08.02710.1016/j.jconrel.2017.08.027 ↗
10. Chen CT, Duan ZQ, Yuan Y, Li RX, Pang L, Liang JM et al (2017) Peptide-22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB. Acs Appl Mater Inter 9:5864–5873. https://doi.org/10.1021/acsami.6b1583110.1021/acsami.6b15831 ↗
11. Chen L, Zeng D, Xu N, Li CP, Zhang WY, Zhu XJ et al (2019) Blood-brain barrier- and blood-brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases. Acs Appl Mater Inter 11:41889–41897. https://doi.org/10.1021/acsami.9b1404610.1021/acsami.9b14046 ↗
12. Chen JH, Ma YC, Du W, Dai TY, Wang YF, Jiang W et al (2020) Furin-instructed intracellular gold nanoparticle aggregation for tumor photothermal therapy. Adv Funct Mater 30:2001566. https://doi.org/10.1002/Adfm.20200156610.1002/Adfm.202001566 ↗
13. Choudhury H, Pandey M, Chin PX, Phang YL, Cheah JY, Ooi SC et al (2018) Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Re 8:1545–1563. https://doi.org/10.1007/s13346-018-0552-210.1007/s13346-018-0552-2 ↗
14. Christie C, Madsen SJ, Peng Q, Hirschberg H (2015) Macrophages as nanoparticle delivery vectors for photothermal therapy of brain tumors. Ther Deliv 6:371–384. https://doi.org/10.4155/Tde.14.12110.4155/Tde.14.121 ↗
15. Clarke MR, Jones B, Squires CLM, Imhoff FM, Harwood DT, Rhodes L et al (2021) Cyclic imine pinnatoxin G is cytotoxic to cancer cell lines via nicotinic acetylcholine receptor-driven classical apoptosis. J Nat Prod 84:2035–2042. https://doi.org/10.1021/acs.jnatprod.1c0041810.1021/acs.jnatprod.1c00418 ↗
16. Cooney T, Yeo KK, Kline C, Prados M, Haas-Kogan D, Chi S et al (2020) Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neuro-Oncol Pract 7:4–10. https://doi.org/10.1093/nop/npz03310.1093/nop/npz033 ↗
17. Cui Y, Zhang M, Zeng F, Jin H, Xu Q, Huang Y (2016) Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Appl Mater Interfaces 8:32159–32169. https://doi.org/10.1021/acsami.6b1017510.1021/acsami.6b10175 ↗
18. Cui YX, Sun JJ, Hao WY, Chen MY, Wang YZ, Xu FH et al (2020) Dual-target peptide-modified erythrocyte membrane-enveloped PLGA nanoparticles for the treatment of glioma. Front Oncol 10:563938. https://doi.org/10.3389/Fonc.2020.56393810.3389/Fonc.2020.563938 ↗
19. Dai TC, Jiang K, Lu WY (2018) Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step Forster resonance energy transfer imaging. Acta Pharm Sin B 8:261–271. https://doi.org/10.1016/j.apsb.2018.01.00410.1016/j.apsb.2018.01.004 ↗
20. de Araujo RV, Santos SD, Ferreira EI, Giarolla J (2018) New advances in general biomedical applications of PAMAM dendrimers. Molecules 23:2849. https://doi.org/10.3390/Molecules2311284910.3390/Molecules23112849 ↗
21. di Polidoro AC, Zambito G, Haeck J, Mezzanotte L, Lamfers M, Netti PA et al (2021) Theranostic design of Angiopep-2 conjugated hyaluronic acid nanoparticles (Thera-ANG-cHANPs) for dual targeting and boosted imaging of glioma cells. Cancers 13:503. https://doi.org/10.3390/Cancers1303050310.3390/Cancers13030503 ↗
22. Dong CY, Hong S, Zheng DW, Huang QX, Liu FS, Zhong ZL et al (2021) Multifunctionalized gold sub-nanometer particles for sensitizing radiotherapy against glioblastoma. Small 17:2006582. https://doi.org/10.1002/Smll.20200658210.1002/Smll.202006582 ↗
23. Du CJ, Liu XP, Hu H, Li HM, Yu LD, Geng DY et al (2020) Dual-targeting and excretable ultrasmall SPIONs for T-1-weighted positive MR imaging of intracranial glioblastoma cells by targeting the lipoprotein receptor-related protein. J Mater Chem B 8:2296–2306. https://doi.org/10.1039/c9tb02391g10.1039/c9tb02391g ↗
24. Ekkelenkamp AE, Elzes MR, Engbersen JFJ, Paulusse JMJ (2018) Responsive crosslinked polymer nanogels for imaging and therapeutics delivery. J Mater Chem B 6:210–235. https://doi.org/10.1039/c7tb02239e10.1039/c7tb02239e ↗
25. Fang F, Zou D, Wang W, Yin Y, Yin T, Hao S et al (2017) Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport. Mater Sci Eng, C Mater Biol Appl 76:1316–1327. https://doi.org/10.1016/j.msec.2017.02.05610.1016/j.msec.2017.02.056 ↗
26. Fu SY, Liang M, Wang YL, Cui L, Gao CH, Chu XY et al (2019a) Dual-modified novel biomimetic nanocarriers improve targeting and therapeutic efficacy in glioma. Acs Appl Mater Inter 11:1841–1854. https://doi.org/10.1021/acsami.8b1866410.1021/acsami.8b18664 ↗
27. Fu QY, Zhao Y, Yang ZZ, Yue QM, Xiao WJ, Chen Y et al (2019) Liposomes actively recognizing the glucose transporter GLUT(1) and integrin alpha(v)beta(3) for dual-targeting of glioma. Arch Pharm 352:e1800219. https://doi.org/10.1002/ardp.20180021910.1002/ardp.201800219 ↗
28. Gao H (2016) Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B 6:268–286. https://doi.org/10.1016/j.apsb.2016.05.01310.1016/j.apsb.2016.05.013 ↗
29. Gao JQ, Lv Q, Li LM, Tang XJ, Li FZ, Hu YL et al (2013) Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials 34:5628–5639. https://doi.org/10.1016/j.biomaterials.2013.03.09710.1016/j.biomaterials.2013.03.097 ↗
30. Gao HL, Yang Z, Zhang S, Pang ZQ, Liu QF, Jiang XG (2014) Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 10:858–867. https://doi.org/10.1016/j.actbio.2013.11.00310.1016/j.actbio.2013.11.003 ↗
31. Grimaudo MA, Concheiro A, Alvarez-Lorenzo C (2019) Nanogels for regenerative medicine. J Control Release 313:148–160. https://doi.org/10.1016/j.jconrel.2019.09.01510.1016/j.jconrel.2019.09.015 ↗
32. Gu J, Al-Bayati K, Ho EA (2017) Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Deliv Transl Res 7:497–506. https://doi.org/10.1007/s13346-017-0368-510.1007/s13346-017-0368-5 ↗
33. Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H et al (2019) Stimulus-responsive polymeric nanogels as smart drug delivery systems. Acta Biomater 92:1–18. https://doi.org/10.1016/j.actbio.2019.05.01810.1016/j.actbio.2019.05.018 ↗
34. Hampton T (2015) Targeting insulin pathways to treat brain tumors. Jama-J Am Med Assoc 313:2114. https://doi.org/10.1001/jama.2015.514010.1001/jama.2015.5140 ↗
35. Han LA, Li JF, Huang SX, Huang RQ, Liu SH, Hu X et al (2011) Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 32:2989–2998. https://doi.org/10.1016/j.biomaterials.2011.01.00510.1016/j.biomaterials.2011.01.005 ↗
36. Han SP, Zheng HY, Lu YP, Sun Y, Huang AH, Fei WD et al (2018) A novel synergetic targeting strategy for glioma therapy employing borneol combination with angiopep-2-modified, DOX-loaded PAMAM dendrimer. J Drug Target 26:86–94. https://doi.org/10.1080/1061186X.2017.134484910.1080/1061186X.2017.1344849 ↗
37. Hashimoto Y, Mukai S, Sasaki Y, Akiyoshi K (2018) Nanogel tectonics for tissue engineering: protein delivery systems with nanogel chaperones. Adv Healthc Mater 7:1800729. https://doi.org/10.1002/Adhm.20180072910.1002/Adhm.201800729 ↗
38. Hassan HAFM, Diebold SS, Smyth LA, Walters AA, Lombardi G, Al-Jamal KT (2019) Application of carbon nanotubes in cancer vaccines: achievements, challenges and chances. J Control Release 297:79–90. https://doi.org/10.1016/j.jconrel.2019.01.01710.1016/j.jconrel.2019.01.017 ↗
39. Ho BN, Pfeffer CM, Singh ATK (2017) Update on nanotechnology-based drug delivery systems in cancer treatment. Anticancer res 37:5975–81. https://doi.org/10.21873/anticanres.1204410.21873/anticanres.12044 ↗
40. Huang W, Liang YW, Sang CC, Mei CM, Li XL, Chen TF (2018) Therapeutic nanosystems co-deliver anticancer drugs and oncogene SiRNA to achieve synergetic precise cancer chemo-gene therapy. Journal of Materials Chemistry B 6:3013–3022. https://doi.org/10.1039/c8tb00004b10.1039/c8tb00004b ↗
41. Jang B, Kwon H, Katila P, Lee SJ, Lee H (2016) Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. Adv Drug Deliver Rev 98:113–133. https://doi.org/10.1016/j.addr.2015.10.02310.1016/j.addr.2015.10.023 ↗
42. Jhaveri A, Deshpande P, Pattni B, Torchilin V (2018) Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release 277:89–101. https://doi.org/10.1016/j.jconrel.2018.03.00610.1016/j.jconrel.2018.03.006 ↗
43. Jiang Y, Yang WJ, Zhang J, Meng FH, Zhong ZY (2018) Protein toxin chaperoned by LRP-1-targeted virus-mimicking vesicles induces high-efficiency glioblastoma therapy in vivo. Adv Mater 30:1800316. https://doi.org/10.1002/Adma.20180031610.1002/Adma.201800316 ↗
44. Jiao XX, Yu Y, Meng JX, He M, Zhang CJ, Geng WQ et al (2019) Dual-targeting and microenvironment-responsive micelles as a gene delivery system to improve the sensitivity of glioma to radiotherapy. Acta Pharm Sin B 9:381–396. https://doi.org/10.1016/j.apsb.2018.12.00110.1016/j.apsb.2018.12.001 ↗
45. Kadari A, Pooja D, Gora RH, Gudem S, Kolapalli VRM, Kulhari H et al (2018) Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy. Eur J Pharm Biopharm 132:168–179. https://doi.org/10.1016/j.ejpb.2018.09.01210.1016/j.ejpb.2018.09.012 ↗
46. Kang T, Jiang MY, Jiang D, Feng XY, Yao JH, Song QX et al (2015) Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharmaceut 12:2947–2961. https://doi.org/10.1021/acs.molpharmaceut.5b0022210.1021/acs.molpharmaceut.5b00222 ↗
47. Kang SM, Duan WJ, Zhang SQ, Chen DW, Feng JF, Qi N (2020) Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics 10:4308–4322. https://doi.org/10.7150/thno.4132210.7150/thno.41322 ↗
48. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E et al (2017) Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23:124–136. https://doi.org/10.1158/1078-0432.CCR-15-153510.1158/1078-0432.CCR-15-1535 ↗
49. Kim JS, Shin DH, Kim JS (2018) Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release 269:245–257. https://doi.org/10.1016/j.jconrel.2017.11.02610.1016/j.jconrel.2017.11.026 ↗
50. Kobayashi H, Watanabe R, Choyke PL (2013) Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 4:81–89. https://doi.org/10.7150/thno.719310.7150/thno.7193 ↗
51. Kuche K, Maheshwari R, Tambe V, Mak KK, Jogi H, Raval N et al (2018) Carbon nanotubes (CNTs) based advanced dermal therapeutics: current trends and future potential. Nanoscale 10:8911–8937. https://doi.org/10.1039/c8nr01383g10.1039/c8nr01383g ↗
52. Kuo YC, Lee CH (2016) Dual targeting of solid lipid nanoparticles grafted with 83–14 MAb and anti-EGF receptor for malignant brain tumor therapy. Life Sci 146:222–231. https://doi.org/10.1016/j.lfs.2016.01.02510.1016/j.lfs.2016.01.025 ↗
53. Lam FC, Morton SW, Wyckoff J, Han TLV, Hwang MK, Maffa A et al (2018) Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun 9:1991. https://doi.org/10.1038/S41467-018-04315-410.1038/S41467-018-04315-4 ↗
54. Large DE, Abdelmessih RG, Fink EA, Auguste DT (2021) Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliver Rev 176:113851. https://doi.org/10.1016/J.Addr.2021.11385110.1016/J.Addr.2021.113851 ↗
55. Leng ZH, Zhuang QF, Li YC, He Z, Chen Z, Huang SP et al (2013) Polyamidoamine dendrimer conjugated chitosan nanoparticles for the delivery of methotrexate. Carbohyd Polym 98:1173–1178. https://doi.org/10.1016/j.carbpol.2013.07.02110.1016/j.carbpol.2013.07.021 ↗
56. Li HM, Tong YN, Bai L, Ye L, Zhong L, Duan XM et al (2018a) Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma. Int J Biol Macromol 107:204–211. https://doi.org/10.1016/j.ijbiomac.2017.08.15510.1016/j.ijbiomac.2017.08.155 ↗
57. Li M, Shi KR, Tang X, Wei JJ, Cun XL, Long Y et al (2018b) Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy. Nanomed-Nanotechnol 14:1833–1843. https://doi.org/10.1016/j.nano.2018.05.00810.1016/j.nano.2018.05.008 ↗
58. Li J, Liang HM, Liu J, Wang ZY (2018c) Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy. Int J Pharmaceut 546:215–225. https://doi.org/10.1016/j.ijpharm.2018.05.04510.1016/j.ijpharm.2018.05.045 ↗
59. Li GM, Wang JH, Xu M, Zhang HX, Tu CG, Yang JB et al (2020) Engineered exosome for NIR-triggered drug delivery and superior synergistic chemo-phototherapy in a glioma model. Appl Mater Today 20:100723. https://doi.org/10.1016/J.Apmt.2020.10072310.1016/J.Apmt.2020.100723 ↗
60. Liang M, Gao CH, Wang YL, Gong W, Fu SY, Cui L et al (2018) Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Drug Deliv 25:1652–1663. https://doi.org/10.1080/10717544.2018.149422310.1080/10717544.2018.1494223 ↗
61. Liang S, Liu Y, Gao T, Liu XQ, Zhang ZP, Mu WW, et al. (2021) An integrated nanoaircraft carrier modulating antitumor immunity to enhance immune checkpoint blockade therapy. Adv Funct Mater. Artn 2106123 https://doi.org/10.1002/Adfm.20210612310.1002/Adfm.202106123 ↗
62. Liu YJ, Yang Z, Huang XL, Yu GC, Wang S, Zhou ZJ et al (2018a) Glutathione-responsive self-assembled magnetic gold nanowreath for enhanced tumor imaging and imaging-guided photothermal therapy. ACS Nano 12:8129–8137. https://doi.org/10.1021/acsnano.8b0298010.1021/acsnano.8b02980 ↗
63. Liu DZ, Cheng Y, Cai RQ, Wang WW, Cui H, Liu M et al (2018b) The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle. Nanomed-Nanotechnol 14:991–1003. https://doi.org/10.1016/j.nano.2018.01.00410.1016/j.nano.2018.01.004 ↗
64. Liu YY, Zheng M, Jiao MZ, Yan CN, Xu S, Du QL et al (2021) Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy. Biomaterials 276:121036. https://doi.org/10.1016/j.biomaterials.2021.12103610.1016/j.biomaterials.2021.121036 ↗
65. Liu XG, Duan YK, Hu DH, Wu M, Chen CJ, Ghode PB et al (2021b) Targeted photoacoustic imaging of brain tumor mediated by neutrophils engineered with lipid-based molecular probe. Acs Mater Lett 3:1284–1290. https://doi.org/10.1021/acsmaterialslett.1c0032910.1021/acsmaterialslett.1c00329 ↗
66. Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G, Chow EK (2018) Clinical applications of carbon nanomaterials in diagnostics and therapy. Adv Mater 30:e1802368. https://doi.org/10.1002/adma.20180236810.1002/adma.201802368 ↗
67. Lu F, Pang Z, Zhao J, Jin K, Li H, Pang Q et al (2017) Angiopep-2-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomed 12:2117–2127. https://doi.org/10.2147/IJN.S12342210.2147/IJN.S123422 ↗
68. Luo MH, Lewik G, Ratcliffe JC, Choi CHJ, Makila E, Tong WY et al (2019) Systematic evaluation of transferrin-modified porous silicon nanoparticles for targeted delivery of doxorubicin to glioblastoma. Acs Appl Mater Inter 11:33637–33649. https://doi.org/10.1021/acsami.9b1078710.1021/acsami.9b10787 ↗
69. Luther DC, Huang R, Jeon T, Zhang XZ, Lee YW, Nagaraj H et al (2020) Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliver Rev 156:188–213. https://doi.org/10.1016/j.addr.2020.06.02010.1016/j.addr.2020.06.020 ↗
70. Lv LY, Li XR, Qian W, Li SN, Jiang Y, Xiong YK et al (2020) Enhanced anti-glioma efficacy by borneol combined with CGKRK-modified paclitaxel self-assembled redox-sensitive nanoparticles. Front Pharmacol 11:558. https://doi.org/10.3389/Fphar.2020.0055810.3389/Fphar.2020.00558 ↗
71. Majumder J, Taratula O, Minko T (2019) Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliver Rev 144:57–77. https://doi.org/10.1016/j.addr.2019.07.01010.1016/j.addr.2019.07.010 ↗
72. Mignani S, Shi XY, Cena V, Rodrigues J, Tomas H, Majoral JP (2021) Engineered non-invasive functionalized dendrimer/dendron-entrapped/complexed gold nanoparticles as a novel class of theranostic (radio) pharmaceuticals in cancer therapy. J Control Release 332:346–366. https://doi.org/10.1016/j.jconrel.2021.03.00310.1016/j.jconrel.2021.03.003 ↗
73. Minaei SE, Khoei S, Khoee S, Karimi MR (2019) Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma. Int J Biochem Cell B 108:72–83. https://doi.org/10.1016/j.biocel.2019.01.01010.1016/j.biocel.2019.01.010 ↗
74. Newton HB (2006) Advances in strategies to improve drug delivery to brain tumors. Expert Rev Neurother 6:1495–1509. https://doi.org/10.1586/14737175.6.10.149510.1586/14737175.6.10.1495 ↗
75. Ni XR, Zhao YY, Cai HP, Yu ZH, Wang J, Chen FR et al (2020) Transferrin receptor 1 targeted optical imaging for identifying glioma margin in mouse models. J Neuro-Oncol 148:245–258. https://doi.org/10.1007/s11060-020-03527-310.1007/s11060-020-03527-3 ↗
76. Niu JX, Wang LY, Yuan M, Zhang JX, Chen H, Zhang YS (2020) Dual-targeting nanocarrier based on glucose and folic acid functionalized pluronic P105 polymeric micelles for enhanced brain distribution. J Drug Deliv Sci Tec 57:101343. https://doi.org/10.1016/J.Jddst.2019.10134310.1016/J.Jddst.2019.101343 ↗
77. Pang ZQ, Gao HL, Yu Y, Chen J, Guo LR, Ren JF et al (2011) Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharmaceut 415:284–292. https://doi.org/10.1016/j.ijpharm.2011.05.06310.1016/j.ijpharm.2011.05.063 ↗
78. Patil SS, Shinde VS, Misra RDK (2018) pH and reduction dual-stimuli-responsive PEGDA/PAMAM injectable network hydrogels via aza-michael addition for anticancer drug delivery. J Polym Sci Pol Chem 56:2080–2095. https://doi.org/10.1002/pola.2916810.1002/pola.29168 ↗
79. Pavitra E, Dariya B, Srivani G, Kang SM, Alam A, Sudhir PR et al (2021) Engineered nanoparticles for imaging and drug delivery in colorectal cancer. Semin Cancer Biol 69:293–306. https://doi.org/10.1016/j.semcancer.2019.06.01710.1016/j.semcancer.2019.06.017 ↗
80. Peng Y, Huang J, Xiao H, Wu T, Shuai X (2018) Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment. Int J Nanomed 13:3467–3480. https://doi.org/10.2147/IJN.S16461110.2147/IJN.S164611 ↗
81. Pucci S, Fasoli F, Moretti M, Benfante R, Di Lascio S, Viani P et al (2021) Choline and nicotine increase glioblastoma cell proliferation by binding and activating alpha 7-and alpha 9-containing nicotinic receptors. Pharmacol Res 163:105336. https://doi.org/10.1016/J.Phrs.2020.10533610.1016/J.Phrs.2020.105336 ↗
82. Qi Y, Liu B, Sun Q, Xiong X, Chen Q (2020) Immune checkpoint targeted therapy in glioma: status and hopes. Front Immunol 11:578877. https://doi.org/10.3389/fimmu.2020.57887710.3389/fimmu.2020.578877 ↗
83. Ramalho MJ, Bravo M, Loureiro JA, Lima J, Pereira MC (2022) Transferrin-modified nanoparticles for targeted delivery of Asiatic acid to glioblastoma cells. Life Sci 296:120435. https://doi.org/10.1016/j.lfs.2022.12043510.1016/j.lfs.2022.120435 ↗
84. Raphey VR, Henna TK, Nivitha KP, Mufeedha P, Sabu C, Pramod K (2019) Advanced biomedical applications of carbon nanotube. Mat Sci Eng C-Mater 100:616–630. https://doi.org/10.1016/j.msec.2019.03.04310.1016/j.msec.2019.03.043 ↗
85. Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z et al (2012) The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33:3324–3333. https://doi.org/10.1016/j.biomaterials.2012.01.02510.1016/j.biomaterials.2012.01.025 ↗
86. Ruan SB, Xiao W, Hu C, Zhang HJ, Rao JD, Wang SH et al (2017) Ligand-mediated and enzyme-directed precise targeting and retention for the enhanced treatment of glioblastoma. Acs Appl Mater Inter 9:20348–20360. https://doi.org/10.1021/acsami.7b0230310.1021/acsami.7b02303 ↗
87. Santos T, Fang X, Chen MT, Wang W, Ferreira R, Jhaveri N et al (2014) Sequential administration of carbon nanotubes and near-infrared radiation for the treatment of gliomas. Front Oncol 4:180. https://doi.org/10.3389/fonc.2014.0018010.3389/fonc.2014.00180 ↗
88. Sharifi M, Attar F, Saboury AA, Akhtari K, Hooshmand N, Hasan A et al (2019) Plasmonic gold nanoparticles: optical manipulation, imaging, drug delivery and therapy. J Control Release 311:170–189. https://doi.org/10.1016/j.jconrel.2019.08.03210.1016/j.jconrel.2019.08.032 ↗
89. Shi W, Cui XX, Shi JL, Chen J, Wang Y (2017) Overcoming the blood-brain barrier for glioma-targeted therapy based on an interleukin-6 receptor-mediated micelle system. Rsc Adv 7:27162–27169. https://doi.org/10.1039/c7ra03208k10.1039/c7ra03208k ↗
90. Shi YN, Jiang Y, Cao JS, Yang WJ, Zhang J, Meng FH et al (2018a) Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes. J Control Release 292:163–171. https://doi.org/10.1016/j.jconrel.2018.10.03410.1016/j.jconrel.2018.10.034 ↗
91. Shi MH, Anantha M, Wehbe M, Bally MB, Fortin D, Roy LO et al (2018) Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats. J Nanobiotechnol 16:77. https://doi.org/10.1186/s12951-018-0404-810.1186/s12951-018-0404-8 ↗
92. Shi XW, Ma R, Lu YP, Cheng Y, Fan XD, Zou JF et al (2020) iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas. Biochem Bioph Res Co 527:117–123. https://doi.org/10.1016/j.bbrc.2020.04.06410.1016/j.bbrc.2020.04.064 ↗
93. Singh I, Swami R, Jeengar MK, Khan W, Sistla R (2015) p-Aminophenyl-alpha-D-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain. Chem Phys Lipids 188:1–9. https://doi.org/10.1016/j.chemphyslip.2015.03.00310.1016/j.chemphyslip.2015.03.003 ↗
94. Sonali SRP, Sharma G, Kumari L, Koch B, Singh S et al (2016) RGD-TPGS decorated theranostic liposomes for brain targeted delivery. Colloid Surface B 147:129–141. https://doi.org/10.1016/j.colsurfb.2016.07.05810.1016/j.colsurfb.2016.07.058 ↗
95. Song PP, Song NN, Li L, Wu MH, Lu ZX, Zhao X (2021) Angiopep-2-Modified Carboxymethyl chitosan-based pH/reduction dual-stimuli-responsive nanogels for enhanced targeting glioblastoma. Biomacromol 22:2921–2934. https://doi.org/10.1021/acs.biomac.1c0031410.1021/acs.biomac.1c00314 ↗
96. Sonju JJ, Dahal A, Singh SS, Jois SD (2021) Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J Control Release 329:624–644. https://doi.org/10.1016/j.jconrel.2020.09.05510.1016/j.jconrel.2020.09.055 ↗
97. Su ZG, Xing L, Chen YN, Xu YR, Yang FF, Zhang C et al (2014) Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol Pharmaceut 11:1823–1834. https://doi.org/10.1021/mp500238m10.1021/mp500238m ↗
98. Su YX, Xie ZW, Kim GB, Dong C, Yang J (2015) Design strategies and applications of circulating cell-mediated drug delivery systems. Acs Biomater Sci Eng 1:201–217. https://doi.org/10.1021/ab500179h10.1021/ab500179h ↗
99. Sukumar UK, Bose RJC, Malhotra M, Babikir HA, Afjei R, Robinson E et al (2019) Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomater 218:119342. https://doi.org/10.1016/j.biomaterials.2019.11934210.1016/j.biomaterials.2019.119342 ↗
100. Sun ZL, Yan XB, Liu YB, Huang LS, Kong C, Qu X et al (2017) Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin. Oncotarget 8:58823–34. https://doi.org/10.18632/oncotarget.1922110.18632/oncotarget.19221 ↗